Locations:

Blood Cancers

January 14, 2019/Cancer/Blood Cancers

Graft Composition in Allogeneic Hematopoietic Cell Transplantation May Be Associated with Patient Outcomes

A closer look at other T-cell subsets

November 28, 2018/Cancer/Blood Cancers

New Drug Approved to Treat Some Patients with Acute Myeloid Leukemia

Response rates as good as or better than other therapies

June 26, 2018/Cancer/Blood Cancers

Cancer Center Offers Chimeric Antigen Receptor T-Cell Therapy

Cleveland Clinic's approach to the therapy

September 7, 2017/Cancer/Blood Cancers

Largest Biomarker Study for Cancer-Related Blood Clots Finds Circulating Tissue Factor Significant

Tumor cells push the body toward a procoagulant state

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

August 31, 2017/Cancer/Blood Cancers

CAR T-Cell Therapy Charts a New Course in U.S. with FDA Approval

FDA approves groundbreaking therapy to fight ALL

April 24, 2017/Cancer/Blood Cancers

Dynamics of Two Mutational Paths in the Progression of MDS

Largest genomic assessment of MDS to date

April 18, 2017/Cancer/Blood Cancers

A Paradigm Shift in CLL Treatment

Optimal sequencing of targeted therapies

January 23, 2017/Cancer/Blood Cancers

Inotuzumab Ozogamicin Improves Outcomes for Relapsed/Refractory Acute Lymphoblastic Leukemia

Study’s findings are welcome news

July 20, 2016/Cancer/Blood Cancers

Novel Agent Holds Promise for Refractory/Relapsed ALL

Phase 3 results reported in NEJM

December 7, 2015/Cancer/Blood Cancers

Trial Finds Advantage in Overall Response Rate for subtypes of MDS Patients Receiving Azacitidine Combination Therapy

Response in patient subgroups shows promise, however

BackPage 6 of 7Next